ESC Premium Access

Risks and outcomes of gastrointestinal malignancies in anticoagulated atrial fibrillation patients experiencing gastrointestinal bleeding

Congress Presentation

About the speaker

Doctor Tze-Fan Chao

Taipei Veterans General Hospital, Taipei (Taiwan)
4 presentations
0 follower

7 more presentations in this session

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with antiphospholipid syndrome: a nationwide cohort study

Speaker: Assistant Professor P. Yang (Seongnam, KR)


Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study

Speaker: Doctor M. Proietti (Milan, IT)


Reduced stroke risk without increased bleeding risk in patients with atrial fibrillation and complicated liver cirrhosis treated with oral anticoagulation

Speaker: Doctor K. Steensig (Aalborg, DK)


Is there a role for half-dose anticoagulation in atrial fibrillation? Randomized comparison of 2 doses of edoxaban in 14,014 patients in ENGAGE AF-TIMI 48

Speaker: Professor J. Steffel (Zurich, CH)


Recommended and non-recommended edoxaban dosing in patients with atrial fibrillation (AF): one-year clinical events from the Global ETNA-AF non-interventional study (NIS)

Speaker: Doctor T. Chao (Taipei, TW)


Access the full session

Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation in ‘Special’ Situations

Speakers: Doctor T. Chao, Assistant Professor P. Yang, Doctor M. Proietti, Doctor K. Steensig, Professor J. Steffel...

About the event


ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb